These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11278149)

  • 1. Physostigmine and cognition in schizotypal personality disorder.
    Kirrane RM; Mitropoulou V; Nunn M; Silverman J; Siever LJ
    Schizophr Res; 2001 Mar; 48(1):1-5. PubMed ID: 11278149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychological performance in schizotypal personality disorder: importance of working memory.
    Mitropoulou V; Harvey PD; Zegarelli G; New AS; Silverman JM; Siever LJ
    Am J Psychiatry; 2005 Oct; 162(10):1896-903. PubMed ID: 16199836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.
    Rosell DR; Zaluda LC; McClure MM; Perez-Rodriguez MM; Strike KS; Barch DM; Harvey PD; Girgis RR; Hazlett EA; Mailman RB; Abi-Dargham A; Lieberman JA; Siever LJ
    Neuropsychopharmacology; 2015 Jan; 40(2):446-53. PubMed ID: 25074637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual-spatial learning and memory in schizotypal personality disorder: continued evidence for the importance of working memory in the schizophrenia spectrum.
    McClure MM; Romero MJ; Bowie CR; Reichenberg A; Harvey PD; Siever LJ
    Arch Clin Neuropsychol; 2007 Jan; 22(1):109-16. PubMed ID: 17161580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memory decline in the aged: treatment with lecithin and physostigmine.
    Drachman DA; Glosser G; Fleming P; Longenecker G
    Neurology; 1982 Sep; 32(9):944-50. PubMed ID: 6287359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory.
    Bentley P; Husain M; Dolan RJ
    Neuron; 2004 Mar; 41(6):969-82. PubMed ID: 15046728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual-spatial working memory performance and temporal gray matter volume predict schizotypal personality disorder group membership.
    Hazlett EA; Lamade RV; Graff FS; McClure MM; Kolaitis JC; Goldstein KE; Siever LJ; Godbold JH; Moshier E
    Schizophr Res; 2014 Feb; 152(2-3):350-7. PubMed ID: 24398009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic enhancement and increased selectivity of perceptual processing during working memory.
    Furey ML; Pietrini P; Haxby JV
    Science; 2000 Dec; 290(5500):2315-9. PubMed ID: 11125148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of varenicline on cognitive function in non-smokers with schizophrenia.
    Kozak K; Dermody SS; Rabin RA; Zack M; Barr MS; Tyndale RF; George TP
    Schizophr Res; 2018 Jul; 197():562-563. PubMed ID: 28291692
    [No Abstract]   [Full Text] [Related]  

  • 11. Visual perception and working memory in schizotypal personality disorder.
    Farmer CM; O'Donnell BF; Niznikiewicz MA; Voglmaier MM; McCarley RW; Shenton ME
    Am J Psychiatry; 2000 May; 157(5):781-8. PubMed ID: 10784472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verbal and nonverbal neuropsychological test performance in subjects with schizotypal personality disorder.
    Voglmaier MM; Seidman LJ; Niznikiewicz MA; Dickey CC; Shenton ME; McCarley RW
    Am J Psychiatry; 2000 May; 157(5):787-93. PubMed ID: 10784473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models.
    Rupniak NM; Field MJ; Samson NA; Steventon MJ; Iversen SD
    Neurobiol Aging; 1990; 11(6):609-13. PubMed ID: 2280804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physostigmine reverses cognitive dysfunction caused by moderate hypoxia in adult mice.
    Bekker A; Haile M; Gingrich K; Wenning L; Gorny A; Quartermain D; Blanck T
    Anesth Analg; 2007 Sep; 105(3):739-43. PubMed ID: 17717233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    McClure MM; Barch DM; Romero MJ; Minzenberg MJ; Triebwasser J; Harvey PD; Siever LJ
    Biol Psychiatry; 2007 May; 61(10):1157-60. PubMed ID: 16950221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.
    Kertzman C; Robinson DL; Litvan I
    Arch Neurol; 1990 Dec; 47(12):1346-50. PubMed ID: 2252453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity.
    Mitropoulou V; Harvey PD; Maldari LA; Moriarty PJ; New AS; Silverman JM; Siever LJ
    Biol Psychiatry; 2002 Dec; 52(12):1175-82. PubMed ID: 12488063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of OROS methylphenidate on academic, behavioral, and cognitive tasks in children 9 to 12 years of age with attention-deficit/hyperactivity disorder.
    Murray DW; Childress A; Giblin J; Williamson D; Armstrong R; Starr HL
    Clin Pediatr (Phila); 2011 Apr; 50(4):308-20. PubMed ID: 21436147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catechol-O-methyltransferase Val158Met genotype variation is associated with prefrontal-dependent task performance in schizotypal personality disorder patients and comparison groups.
    Minzenberg MJ; Xu K; Mitropoulou V; Harvey PD; Finch T; Flory JD; New AS; Goldman D; Siever LJ
    Psychiatr Genet; 2006 Jun; 16(3):117-24. PubMed ID: 16691129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder.
    Kirrane RM; Mitropoulou V; Nunn M; New AS; Harvey PD; Schopick F; Silverman J; Siever LJ
    Neuropsychopharmacology; 2000 Jan; 22(1):14-8. PubMed ID: 10633486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.